Vaccine · 2025
Community interpretation of a consent form and willingness to participate in a Nipah virus vaccine trial in Bangladesh.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nahar Nazmun, Parveen Shahana, Gurley Emily S, Ghosh Probir Kumar, Jabeen Ishrat, Haidar Md Rifat, Jahan Farhat, Munim Mohammad Saeed, Ali Md Wazed, Shirin Tahmina, Banu Sayera, Chowdhury Atique Iqbal, Alam Asraful, Dawes Brian E, Fusco Joan, Monath Thomas P, Heppner Gray, Luby Stephen P
Аннотация
INTRODUCTION: Clinical trials conducted in low resource settings of vaccines against unlikely pandemics generate practical barriers to achieving genuine informed consent. Uncertainty over the likelihood of the occurrence of emerging disease threats complicates risk-benefit considerations. We explored how people interpreted the language of a draft consent form for a Phase II trial of a vaccine against Nipah virus (NiV), a lethal bat-borne zoonosis, and assessed their willingness to participate after learning about the trial procedures.
METHODS: We conducted a mixed-methods study collecting data from residents of Dhaka city, and Faridpur District between December 2021 and November 2022. Our qualitative team revised a draft consent form with input from the community, while the quantitative team conducted face-to-face interviews of 978 household heads making vaccine and treatment decisions.
RESULTS: We presented the consent form to 20 respondents. They expressed a desire to learn more about NiV disease and sought clarification on the vaccine trial process, use of a placebo, privacy and confidentiality, potential side effects, and compensation procedures. During the quantitative survey, among 328 respondents who indicated a willingness to participate in the vaccine trial, only 1 % (3/328) were familiar with the concept of a placebo. After the quantitative data collection team explained the meaning of a placebo, 61 % (199/328) expressed their willingness to participate in the trial.
CONCLUSION: Our data suggest that obtaining informed consent for vaccine trials against pathogen with pandemic potentials is feasible but requires a commitment to eliciting study participants' perspectives and tailoring study materials to address their concerns and gaps in understanding.
METHODS: We conducted a mixed-methods study collecting data from residents of Dhaka city, and Faridpur District between December 2021 and November 2022. Our qualitative team revised a draft consent form with input from the community, while the quantitative team conducted face-to-face interviews of 978 household heads making vaccine and treatment decisions.
RESULTS: We presented the consent form to 20 respondents. They expressed a desire to learn more about NiV disease and sought clarification on the vaccine trial process, use of a placebo, privacy and confidentiality, potential side effects, and compensation procedures. During the quantitative survey, among 328 respondents who indicated a willingness to participate in the vaccine trial, only 1 % (3/328) were familiar with the concept of a placebo. After the quantitative data collection team explained the meaning of a placebo, 61 % (199/328) expressed their willingness to participate in the trial.
CONCLUSION: Our data suggest that obtaining informed consent for vaccine trials against pathogen with pandemic potentials is feasible but requires a commitment to eliciting study participants' perspectives and tailoring study materials to address their concerns and gaps in understanding.